On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...

SKY-0515 is a daily oral drug designed to lower both huntingtin, the protein that drives HD, and PMS1, a DNA repair protein linked to somatic CAG repeat expansion. Researchers hope this dual-target ...

In a recent study, scientists created a chemical that breaks down expanded huntingtin HTT clumps in HD cells and mouse models. This chemical finds HTT clumps and targets them to be broken down or ...

uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License ...

Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...

A recent collaboration between researchers at the University of Leiden and the Huntington Expertise Center Topaz Overduin in the Netherlands has focused on an important yet often overlooked part of ...

The Total Functional Capacity scale, or TFC, was developed in 1979 by researchers Dr. Stanley Fahn and the late Dr. Ira Shoulson, founder of the Huntington Study Group. They wanted to describe the ...

Anew study using precise gene editing in a Huntington’s disease (HD) mouse model provides evidence that a small fragment of the huntingtin (HTT) protein, called HTT1a, is a central driver of HD. By ...

A new collaboration between researchers at Indiana University Southeast and Bellarmine University in Kentucky, both in the USA, aimed to investigate what happens when a physical therapist and a music ...

Greetings from Day 2 of the CHDI HD Therapeutics Conference! HDBuzz continues to provide summaries of the exciting talks from HD scientists gathered in Palm Springs from around the world. This day’s ...

For individuals in the HD “grey zone” between 36-39 repeats, an understanding of when symptoms may arise and what kind of symptoms is critical. A new study sheds light on different sequence patterns ...

A new Huntington’s disease (HD) clinical trial has reached an important milestone: the first participants have now been dosed in POINT-HD, a Phase 1 study testing a new, selective huntingtin-lowering ...